ORG 101
Alternative Names: Acne vulgaris vaccine - Origimm; ORG101; ORI-001; ORI-A-ce001Latest Information Update: 28 Jan 2025
Price :
$50 *
At a glance
- Originator Origimm
- Class Antiacnes; Skin disorder therapies; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acne vulgaris
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for phase-I development in Acne-vulgaris(Prevention) in Germany (Injection)
- 28 Dec 2024 No recent reports of development identified for phase-I development in Acne-vulgaris(In the elderly, In adults) in Germany (IM, Injection)
- 27 Nov 2023 Sanofi Pasteur completes a phase I trial in Acne vulgaris in Germany (IM) (NCT05131373)